We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byAbby Houghton
Modified about 1 year ago
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Opportunities to bridge the technology gap between academia and industry. The view from one pharma
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY AstraZeneca Major world wide Pharma Active in more than 100 countries world wide 2008 sales of $31.6 billion >3% increase on 2007 65,000 employees world wide 12,000 staff in R&D >$5 billion invested in R&D 17 principle R&D centers across 8 countries Focus on 6 therapy areas Oncology Cardio Vascular Respiratory and Inflamation Infection Neuroscience Gastrointestinal
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Pipeline of NCEs as of Jan 2009 Phase 1 trial 23 small molecules 10 biologicals Phase 2 trials 26 small molecules 5 biologicals Phase 3/ registrations 9 small molecules 1 biological Data from 2008 annual report
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Acquisitions and Licensing 35-40 major business development transactions (2008 annual report) Some examples of recent acquisitions Biologicals Cambridge Antibody Technologies MedImmune Infection Arrow Therapeutics Oncology KuDos Pharmaceuticals Licensing 11 of the NCEs currently in clinical trials are partnered products
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Links with Academic Institutions Within the UK 2008 started collaboration with Cancer Research UK – Linking an AstraZeneca development compound with the charities Clinical Development Partnership program Royal Marsden NHS foundation trust – accessing imaging technology to study the impact of Recentin on solid tumours Manchester University – strategic alliance to look at imaging biomarkers. In addition there are links through Manchester University to the National Cancer Centre Singapore Newcastle University – linked with Astrazeneca via Cancer Research Technology Ltd and KuDOS to study DNA-PK inhibitors MRC – 4 PhDs BBSRC – AstraZeneca linked with the Babraham Institute Division of Signal Transduction Therapy – University of Dundee
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Links with Overseas Academics ICC – Innovation Centre China ($100M investment) University of Washington St Louis – Investigation in to Alzheimer’s Disease to find better ways of diagnosis and treatment Columbia University Medical Center – Identification of new targets and novel therapies for type 2 diabetes and obesity Virginia Tech and Mayo Clinic – licensing agreement for the triple reuptake inhibitor for treatment of depression University of Texas MD Anderson Cancer Center – Studying cancer related pain Clinical studies and alliances with several US cancer institutes including Mass General Hospital, Vanderbilt-Ingram Cancer Center, University of Colorado and National Cancer Institue
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Technology Collaborations Silence Therapeutics – novel system for using siRNA molecules to target respiratory disease Cell Signaling Technology – PhosphoScan R – CST generated antibodies to phosphorylated peptides used to IP proteins from cell lysates. These are analysed by LC-MS to monitor changes in the levels of phosphorlyation within the cell during treatment with potential kinase inhibitors Astex Therapeutics – fragment based drug discovery – expertise in NMR screening, crystalography and Isothermal calorimetry
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Building a partnership with AstraZeneca Strategic Planning and Business Development (SPBD) Group Main role is to manage in-licensing activities Aligned with therapy areas Also involved with out licensing, spin offs, risk sharing deals Established a Master agreement system for main collaborators Manchester Cancer Research Centre Royal Marsden Hospital NKI-AVL – Netherlands Cancer Institute Strategic Alliances Group Science and Technology Alliances Group Collaborations relating to technology which is applicable across therapy areas Advanced Science and Technology Lab – ASTL
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Areas of interest Chemistry New synthetic methodologies Novel lead generation technologies Predictive QSAR methodologies Predictive Biology High Content Screening technologies Novel physiological cell based efficacy screening technologies Target validation methodologies Improved methodologies to predict safety/toxicity In silico simulation In vivo predictive models In vivo imaging Predictive medicine Rapid biomarker analysis techniques Imaging to provide functional measurements of disease activity Knowledge management/informatics Structured searching and text mining Patent informatics
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Funding Internal Innovation funding <$1M Should not include capital purchases Aim to identify new and novel technologies to improve our lead generation screening capability Partnerships with charitable organisations and governments BBSRG, MRC etc Corporate funding Direct from research areas – very limited Risk sharing deals AZ contribute with resources and knowledge FTE Lab space Compound libraries Chemistry In vitro/ In vivo testing Share rewards between AZ and academic/biotech
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY What can AZ offer Large and ever expanding compound collection 4 HTS centres across the globe supporting 6 therapy areas 2 in UK 1 in Sweden 1 in USA Highly automated screening platforms for both primary and secondary screening Systems from many suppliers Beckman – motorman core systems Agilent (V11) - Biocells The Automation Partnership - Asset RTS HighRes Biosolutions – Microstar systems ThermoFisher – CRS F3 automation systems PAA – Elisa workstations and integrated acoustic dispensing systems Extensive experience and proven track record in drug discovery Technology teams (ASTL, CTT) – role is to evaluate new technologies
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Contact information Chris Yochim – SPBD External Relations email@example.com Iain Comley – Science and Technology Alliances firstname.lastname@example.org Kay Tait – Oncology and Infection SPBD email@example.com Jonathan Wingfield – Cancer Technology Team firstname.lastname@example.org
Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Opportunities to bridge the technology gap between academia and industry. The view.
MRC Technology an independent life science medical research charity Biotech & Money 2016 Mr Andrew Mercieca, Director of Finance
Partnering for Growth Thomas Jefferson University, June 7th, 2013 Chris Yochim, Director, External Relations Strategic Partnering and Business Development.
Aberdeen Confidence in Concept Fund Prof Phil Hannaford Vice Principal – Research & Knowledge Exchange.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
2nd Panel, Best Practices: “ IPR in Successful University-Industry Collaborations” Dr. Tamar Raz, CEO Hadasit, the Technology Transfer Company of Hadassah.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Partnering with Eli Lilly and Company. Lilly at a Glance Founded in 1876 in Indianapolis, Indiana $18.71B sales in ,600 employees worldwide Operations.
Innovative Drug Discovery The EUD-GK-91 Program: Targeting Oncogenic Kinases & Drug Resistance Mutations Mauro Angiolini, PhD 26 th April 2016, BioTrinity.
A truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL.
An Academic Model to Bridge the Valley of Death April 17, 2009 Scott Weir, PharmD, PhD Institute for Advancing Medical Innovation University of Kansas.
This is MEDIVIR OUR research is based on the know how of proteases and polymerases. The aim is to have a steady flow of CDs into clinical development.
The pharmaceutical R&D process Use Discovery years, costly ($30 Mn – $1300Mn) Development.
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
1 Presentation title - edit in the Master slide 1 Current Investment Opportunities Professor Rory Shaw, Medical Director, Healthcare UK, UKTI.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
1 Dr Neil Murray BioInfect th November 2013.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Bindley Bioscience Center Vision: Nurture interactive communication and interdisciplinary discovery with flexible laboratory project spaces and an open.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
From the Valley of Death to the Bridge of Life: Models for De-Risking Early Translational Projects from Around the World.
Indiana Institute For Personalized Medicine David A Flockhart MD, PhD Professor of Medicine, Genetics and Pharmacology Indiana University.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
NoWCADD Progress Report 2015
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
OXFORD IMPEDANCE DIAGNOSTICS Low cost, high sensitivity medical diagnostics Mr Andy Anderson Chief Executive Officer.
SGC OxfordSGC TorontoSGC Stockholm How Canada might develop its drug discovery sector.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
David M. Pollock Medical College of Georgia Discovery-Academia.
MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager University of Glasgow Industry Day: 24 September.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
Dr Claes Wilhelmsson Executive Director Research & Development Innovation and the life sciences.
BRIAN A. MARKISON Chairman, President and Chief Executive Officer SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE.
Knowledge Commons: The Case of the Biopharmaceutical Industry Arti K. Rai Duke Law School.
The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.
Intellectual Property Rights Margaret Lawlor Business Development Manager Faculty of Medical Sciences 3rd October 2013 copyright©NewcastleUniversity 2013.
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.
Forum On Financing Biotechs: Partnering The Biotech Perspective May 15, 2002 Celia Courchene VP, Business Development Xenon Genetics Inc. The Biotech Perspective.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
West Midlands Academic Health Science Network Mental Health Clinical Priority Event October 10 th, 2013 Peter Lewis Medical Director, Birmingham and Solihull.
Working in and career progression within an academic clinical trials unit Helen Thorpe Principal Statistician Clinical Trials Research Unit (CTRU) University.
Galapagos: a new force in drug discovery Onno van de Stolpe – CEO IEX Beleggen in Biotech Dag May 20, 2006.
BioMarker Strategies biotrinity 2016 London April Functional Profiling to Guide Cancer Drug Development and Treatment Selection.
International Research for Global Health NAEJA Pharmaceutical Inc. INTEGRATED MEDICINAL CHEMISTRY.
West Midlands Academic Health Science Network Tony Davis West Midlands AHSN interim board.
© 2017 SlidePlayer.com Inc. All rights reserved.